Us Bancorp \De\ Editas Medicine, Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 6,056 shares of EDIT stock, worth $7,267. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,056

Previous 4,426 36.83%

Holding current value

$7,267

Previous $15,000 53.33%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	BUY	$1.2 - $3.76 $1,956 - $6,128	1,630 Added 36.83%	6,056 $7,000
Q3 2024 Oct 28, 2024	BUY	$3.39 - $5.96 $10,925 - $19,209	3,223 Added 267.91%	4,426 $15,000
Q2 2024 Aug 06, 2024	BUY	$4.67 - $7.28 $364 - $567	78 Added 6.93%	1,203 $5,000
Q1 2024 May 07, 2024	BUY	$7.03 - $11.07 $2,172 - $3,420	309 Added 37.87%	1,125 $8,000
Q4 2023 Feb 09, 2024	SELL	$6.25 - $11.11 $5,550 - $9,865	-888 Reduced 52.11%	816 $8,000
Q3 2023 Nov 03, 2023	SELL	$6.92 - $9.31 $602 - $809	-87 Reduced 4.86%	1,704 $13,000
Q2 2023 Aug 09, 2023	SELL	$6.36 - $11.47 $2,868 - $5,172	-451 Reduced 20.12%	1,791 $14,000
Q1 2023 May 09, 2023	BUY	$7.03 - $11.53 $7,718 - $12,659	1,098 Added 95.98%	2,242 $16,000
Q4 2022 Feb 13, 2023	SELL	$8.32 - $13.21 $9,975 - $15,838	-1,199 Reduced 51.17%	1,144 $10,000
Q3 2022 Oct 27, 2022	SELL	$12.16 - $19.42 $9,326 - $14,895	-767 Reduced 24.66%	2,343 $29,000
Q2 2022 Aug 01, 2022	SELL	$9.99 - $21.35 $95,794 - $204,725	-9,589 Reduced 75.51%	3,110 $37,000
Q1 2022 May 11, 2022	BUY	$14.08 - $27.63 $21,401 - $41,997	1,520 Added 13.6%	12,699 $243,000
Q4 2021 Feb 11, 2022	SELL	$26.55 - $40.57 $225,887 - $345,169	-8,508 Reduced 43.22%	11,179 $296,000
Q3 2021 Nov 10, 2021	BUY	$39.27 - $72.94 $373,654 - $694,024	9,515 Added 93.54%	19,687 $809,000
Q2 2021 Aug 05, 2021	SELL	$31.29 - $56.64 $92,649 - $167,711	-2,961 Reduced 22.55%	10,172 $577,000
Q1 2021 Apr 28, 2021	BUY	$39.71 - $90.58 $158,840 - $362,320	4,000 Added 43.8%	13,133 $551,000
Q4 2020 Feb 04, 2021	BUY	$27.07 - $84.35 $135,404 - $421,918	5,002 Added 121.08%	9,133 $641,000
Q3 2020 Nov 10, 2020	SELL	$28.06 - $37.16 $79,437 - $105,199	-2,831 Reduced 40.66%	4,131 $116,000
Q2 2020 Aug 07, 2020	SELL	$18.5 - $34.34 $261,738 - $485,842	-14,148 Reduced 67.02%	6,962 $205,000
Q1 2020 May 13, 2020	BUY	$14.88 - $32.78 $7,440 - $16,390	500 Added 2.43%	21,110 $419,000
Q4 2019 Feb 04, 2020	BUY	$19.49 - $32.63 $367,678 - $615,564	18,865 Added 1081.09%	20,610 $610,000
Q3 2019 Nov 08, 2019	BUY	$22.49 - $26.81 $12,257 - $14,611	545 Added 45.42%	1,745 $39,000
Q2 2019 Aug 13, 2019	SELL	$20.48 - $27.76 $4,710 - $6,384	-230 Reduced 16.08%	1,200 $30,000
Q1 2019 May 08, 2019	BUY	$19.43 - $26.41 $9,326 - $12,676	480 Added 50.53%	1,430 $35,000
Q3 2018 Nov 01, 2018	SELL	$27.65 - $38.39 $5,530 - $7,678	-200 Reduced 17.39%	950 $30,000
Q2 2018 Aug 08, 2018	SELL	$31.4 - $41.01 $14,789 - $19,315	-471 Reduced 29.06%	1,150 $41,000
Q1 2018 May 08, 2018	BUY	$29.84 - $44.08 $24,498 - $36,189	821 Added 102.63%	1,621 $54,000
Q3 2017 Nov 13, 2017	BUY	$15.81 - $24.01 $12,648 - $19,208	800	800 $19,000

Others Institutions Holding EDIT

# of Institutions

240

Shares Held

57.4M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $82.5M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account